BIORA THERAPEUTICS, INC. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2019 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Biora Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2019 to Q3 2024.
  • Biora Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$18.4M, a 74.9% increase year-over-year.
  • Biora Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$31.5M, a 74.2% increase year-over-year.
  • Biora Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$124M, a 225% decline from 2022.
  • Biora Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$38.2M, a 84.6% increase from 2021.
  • Biora Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$247M, a 28.5% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$31.5M -$18.4M +$55.1M +74.9% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-14
Q2 2024 -$86.6M $6.47M +$24.3M Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-14
Q1 2024 -$111M -$4.19M +$13.3M +76% Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-14
Q4 2023 -$124M -$15.4M -$1.69M -12.3% Oct 1, 2023 Dec 31, 2023 10-K 2024-04-01
Q3 2023 -$122M -$73.5M -$68.3M -1336% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q2 2023 -$54.1M -$17.8M -$12.3M -223% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-14
Q1 2023 -$41.8M -$17.4M -$3.63M -26.3% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-14
Q4 2022 -$38.2M -$13.7M +$79.2M +85.2% Oct 1, 2022 Dec 31, 2022 10-K 2023-03-30
Q3 2022 -$117M -$5.11M +$38.6M +88.3% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 -$156M -$5.51M +$73M +93% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-13
Q1 2022 -$229M -$13.8M +$18.5M +57.2% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-13
Q4 2021 -$247M -$92.9M -$17.3M -23% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-30
Q3 2021 -$230M -$43.7M +$3.32M +7.06% Jul 1, 2021 Sep 30, 2021 10-K 2023-03-30
Q2 2021 -$233M -$78.5M -$25.7M -48.8% Apr 1, 2021 Jun 30, 2021 10-K 2023-03-30
Q1 2021 -$208M -$32.3M -$15.1M -88.1% Jan 1, 2021 Mar 31, 2021 10-K 2023-03-30
Q4 2020 -$193M -$75.5M -$25.1M -49.6% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-28
Q3 2020 -$167M -$47.1M +$10.1M +17.6% Jul 1, 2020 Sep 30, 2020 10-K 2022-03-28
Q2 2020 -$178M -$52.8M -$36.4M -222% Apr 1, 2020 Jun 30, 2020 10-K 2022-03-28
Q1 2020 -$141M -$17.2M +$6.87M +28.6% Jan 1, 2020 Mar 31, 2020 10-K 2022-03-28
Q4 2019 -$148M -$50.5M Oct 1, 2019 Dec 31, 2019 10-K 2021-03-18
Q3 2019 -$57.1M Jul 1, 2019 Sep 30, 2019 10-K 2021-03-18
Q2 2019 -$16.4M Apr 1, 2019 Jun 30, 2019 10-K 2021-03-18
Q1 2019 -$24M Jan 1, 2019 Mar 31, 2019 10-K 2021-03-18
* An asterisk sign (*) next to the value indicates that the value is likely invalid.